Bebtelovimab USG Supply Ending

Please be aware of the following important changes regarding the United States Government (USG) supply of Bebtelovimab:

1. Bebtelovimab USG supply is expected through the week of August 15th at full threshold and August 22nd at lower threshold.

2. Bebtelovimab is expected to be commercially available for purchase starting the week of August 15, 2022. States/territories and providers will be eligible to purchase directly through the distributor; Lilly is not planning state-specific procurement contracts. Information on how commercial access to Bebtelovimab can be found in the next section.

As commercial product becomes available, please consider leveraging USG supply to fill gaps for the under and uninsured within your jurisdictions.

Consequently, we encourage you to plan accordingly and be prepared for potential limitations in Bebtelovimab order fulfillment.

At this time we are not certain when Bebtelovimab ordering capabilities will be turned off in HPoP, but please be aware that supply is low and is not expected to be replenished by the federal government once depleted. Additionally, Bebtelovimab reporting requirements even after the end of USG supply is currently being discussed and more information is expected soon.

Paxlovid Dispensing Rates in Various SVI Localities

In reviewing administration data and comparing against hospitalizations, it revealed that Paxlovid is being dispensed at a lower rate in areas of medium to high social vulnerability index (SVI) across the Commonwealth (Image 1). Some of the reasons for the low dispensing rates in these communities include:

- Patients having the knowledge and resources to test for COVID-19 upon symptom onset
- Patients having the knowledge and resources to access a healthcare provider if positive
- Providers prescribing alternative therapies, including Molnupiravir and Bebtelovimab

Paxlovid is available at clinical sites in these communities and medium and high SVI counties actually have a higher number of courses per population pre-positioned than compared to low SVI counties (Image 2). We strongly encourage providers to assess all COVID-19 positive patients for Paxlovid eligibility and prescribe Paxlovid if appropriate. Providers can locate Paxlovid using the COVID-19 therapeutic locator tool.
If you’d like facility specific information please reach out to covid19therapeutics@vdh.virginia.gov.

**Image 1. Paxlovid Courses Dispensed and New COVID Hospitalizations per 100K by EDI Category**

Courses Dispensed per 100K

<table>
<thead>
<tr>
<th>EDI Category</th>
<th>Courses Dispensed per 100K</th>
<th>Hospitalizations per 100K</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low</td>
<td>97</td>
<td></td>
</tr>
<tr>
<td>Mid</td>
<td>41</td>
<td></td>
</tr>
<tr>
<td>High</td>
<td>21</td>
<td></td>
</tr>
</tbody>
</table>

**Image 2. Paxlovid Availability in Low, Medium and High SVI localities as of August 3rd, 2022**

Paxlovid Courses Available per 100k Population, by County SVI Category

<table>
<thead>
<tr>
<th>SVI Category</th>
<th>Courses Available per 100k Population</th>
</tr>
</thead>
<tbody>
<tr>
<td>High</td>
<td>479.29</td>
</tr>
<tr>
<td>Mid</td>
<td>493.72</td>
</tr>
<tr>
<td>Low</td>
<td>386.86</td>
</tr>
</tbody>
</table>
Deployment of Additional Paxlovid Courses by Feds

Equitable distribution of COVID-19 therapeutics remains a high priority. In an effort to reach vulnerable communities, the federal government launched a new initiative to pre-position Paxlovid in areas of high social vulnerability. Emails were sent to nearly 9000 providers for a one-time distribution of 20 courses of Paxlovid. The outreach targeted sites in counties with high SVI and low dispensing rates of oral antivirals. The goal was to make the product more readily available to quickly treat patients in vulnerable areas.
Bebtelovimab Commercial Access

Sites with existing AmerisourceBergen Accounts:
- Immediate access to Bebtelovimab will be granted to all existing AmerisourceBergen accounts

Sites without an existing AmerisourceBergen Account:
- Sites will need to register for an AmerisourceBergen account
- Contact: asdaccountsetup@amerisourcebergen.com

AmerisourceBergen will sell to licensed and approved customers regardless of current HPoP participation.

Additional Support: For any questions regarding access to Bebtelovimab contact c19therapies@amerisourcebergen.com

Paxlovid Shelf-Life Extension: Drug Information Update

FDA has authorized extended expiration dates for these lots to reflect the 12-month product shelf-life (see Table 1 below), when stored according to the storage conditions detailed in the Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid

Table 1: Extended Expiry Dating for Paxlovid (nirmatrelvir tablets and ritonavir tablets co-packaged for oral use) Authorized under EUA 105

<table>
<thead>
<tr>
<th>Lot #</th>
<th>Extended Expiry Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>FL4516</td>
<td></td>
</tr>
<tr>
<td>FL4517</td>
<td></td>
</tr>
<tr>
<td>FR7229</td>
<td></td>
</tr>
<tr>
<td>FL9088</td>
<td></td>
</tr>
</tbody>
</table>

The initial 3 lots were extended from 7/31 to 10/31/22.

4th lot was extended from 8/31 to 11/30/22

Clinical updates

EVUSHELD Spotlight

EVUSHELD Remains Readily Available for Use!
- ASPR has partnered with AstraZeneca to establish an additional pathway for providers to access EVUSHELD for use with eligible patients. Individual providers and smaller sites of care that DO NOT CURRENTLY receive EVUSHELD through the HHS Health Partner Order Portal (or HPoP) distribution process can now order small, limited quantities of product (1-3 patient courses) directly from the manufacturer, AstraZeneca, through Evusheld’s sole distributor, AmerisourceBergen.
• Providers/Sites WITH an HPoP account/receiving product via HPoP should continue to order through HPoP.
• AstraZeneca established a helpline to receive general EVUSHELD product information as well as guidance for ordering. Please contact the EVUSHELD Helpline at 1-833-EVUSHELD (1-833-388-7453) to learn more.

EVUSHELD is available at some Federal Pharmacy Partner locations, see table below:

<table>
<thead>
<tr>
<th>Pharmacy Partner</th>
<th>Including:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albertsons</td>
<td>Alberstons, Acme, Jewel-Osco, Pavilions, Randalls, Safeway, Start Market, Vons CPESN</td>
</tr>
<tr>
<td>Hy-Vee</td>
<td>Amber Specialty Pharmacy</td>
</tr>
<tr>
<td>Managed Healthcare Associates (MHA)</td>
<td>Thrifty White</td>
</tr>
</tbody>
</table>

**EVUSHELD Lot #AZ2200491 Expires 8/31/2022**
EVUSHELD Lot #AZ2200491 (also referred to as Lot 12) continues to have an expiration date of August 31, 2022. If your facility has any EVUSHELD on site that is this lot/expiration, we advise that your providers administer these doses first in order to use it before it expires and prevent wastage.

**EVUSHELD Dosing**
The AstraZeneca Call Center remains available should you have questions regarding the updated dosing guidance and/or the shelf-life extension for EVUSHELD. The AstraZeneca Call Center can be reached at 1-800-236-9933.

---

**Allocation data**

**Total Allocations to Therapeutic Administration Sites (07/21/2022 - 08/04/2022):**

<table>
<thead>
<tr>
<th>Therapeutic (mAB &amp; OAV*)</th>
<th>Central</th>
<th>Eastern</th>
<th>Northern</th>
<th>Northwest</th>
<th>Southwest</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bebtelovimab</td>
<td>270</td>
<td>185</td>
<td>285</td>
<td>225</td>
<td>285</td>
<td>1250</td>
</tr>
<tr>
<td>Evusheld</td>
<td>192</td>
<td>216</td>
<td>528</td>
<td>96</td>
<td>48</td>
<td>1080</td>
</tr>
<tr>
<td>Lagevrio (Molnupiravir)</td>
<td>24</td>
<td>24</td>
<td>0</td>
<td>0</td>
<td>72</td>
<td>120</td>
</tr>
<tr>
<td>Paxlovid</td>
<td>20</td>
<td>320</td>
<td>1500</td>
<td>200</td>
<td>420</td>
<td>2460</td>
</tr>
<tr>
<td>Renal Paxlovid</td>
<td>15</td>
<td>45</td>
<td>95</td>
<td>5</td>
<td>115</td>
<td>275</td>
</tr>
</tbody>
</table>
*Oral Antiviral numbers presented do not include those allocated to Community Pharmacy Enhanced Services Network. These Oral Antiviral courses were bulk ordered and distribution to individual site locations is managed by respective Federal Retail Pharmacy Therapeutic Program (FRPTP) partners, VDH does not have visibility of course distribution to each region.

*Please reference the Outpatient Therapeutic Portfolio- Jurisdiction Allocations for more detail.

**Redistribution**

VDH can redistribute therapeutics within our Commonwealth. Any providers wishing to make their therapeutics available for transfer can do so by clicking the link “Redistribute Excess Therapeutics” on the [VDH home page](https://www.vdh.virginia.gov). The VDH Therapeutics team will prioritize these available therapeutics before pulling from federal supplies whenever it is advantageous to do so.


---

**Resources and Tools**

**Monkeypox**

The CDC and VDH are closely tracking the Monkeypox outbreak. For further information and guidance please see [Treatment of Monkeypox: Information for Virginia Healthcare Providers](https://www.vdh.virginia.gov).


**Link to Sign Up for the Newsletter:**

Did your colleague share this newsletter with you, and you'd like to sign up to receive it directly? Do you know of a colleague that would benefit from receiving information on therapeutics from VDH? Click [here to sign up](https://www.vdh.virginia.gov)!

**VDH Therapeutics Website for Healthcare Providers**

Check out the VDH Therapeutics webpage [here](https://www.vdh.virginia.gov). Reach out to [COVID19Therapeutics@vdh.virginia.gov](mailto:COVID19Therapeutics@vdh.virginia.gov) for questions, comments, or feedback on information you'd like to see.

**COVID-19 Therapeutics Webinars and Open Forum Calls for Providers**

- VDH is continuing to facilitate webinars and open forums monthly. See below for links to [register](https://www.vdh.virginia.gov)!


Other resource links:

VDH: COVID-19 Therapeutics FAQs for Providers
VDH: Guidance on Expiring & Expired Therapeutics
VDH: EVUSHELD Fact Sheet for Providers
VDH: Lagevrio (Molnupiravir) Prescribing Checklist
VDH: Paxlovid Prescribing Checklist
VDH: Paxlovid Prescribing Checklist- Pharmacists
HHS: ASPR Test to Treat Fact Sheet

Find where to access therapeutics here.